BSE filing, NSE: MORARKFI. Summary written from the filing by ALFA Finder's alert engine.
Morarka Finance Ltd: key numbers
- Share price
- ₹56.97
- Market cap
- ₹25.65 Cr
- Revenue (annual)
- ₹2.22 Cr
- Net profit (annual)
- ₹1.43 Cr
- P/E (TTM)
- 37.4×Sector 19.1×
- Promoter holding
- 66.78%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Morarka Finance Ltd
All →Morarka Finance Legal & Regulatory
Morarka Finance received a BSE fine of Rs.1,22,720 inclusive of GST for late filing of its FY2025-26 annual report. The company disputes intent and has sought a waiver.
- Value
- ₹0.01 Cr
Morarka Finance Annual Report
Morarka Finance filed its 2025-26 Annual Report and AGM notice for the July 15, 2026 meeting. Agenda includes Pranay Morarka's Managing Director appointment and remuneration.
Morarka Finance Q2 FY27 Results: Net Profit ₹0.1 Cr, Down 90.9% YoY
Morarka Finance Ltd reported revenue from operations of ₹0.3 Cr (-81.2% YoY) and net profit of ₹0.1 Cr (-90.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹0.1 Cr · -90.9% YoY
Morarka Finance Other Announcement
Morarka Finance Ltd has filed its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI LODR regulations.
Morarka Finance Board Meeting Date
Morarka Finance scheduled a board meeting for 21 Oct 2026 to approve Q2 FY27 unaudited results. No financial figures or decisions are reported in this advance intimation.
Morarka Finance Regulatory Approval
Morarka Finance has received RBI approval for the appointment of Mr. Pranay G. Morarka as the Managing Director of the company.
Other financial results announcements
All →Asit C Mehta Financial Services Q2 FY27 Results: Net Loss of ₹0.3 Cr
Asit C Mehta Financial Services Ltd reported revenue from operations of ₹19.2 Cr (-11.5% YoY) and a net loss of ₹0.3 Cr for Q2 FY27.
- Key figure
- Net loss ₹0.3 Cr
Genpharmasec Financial Results
Genpharmasec approved unaudited half-year results and planned sale of its wholly owned subsidiary Clinigenome India. Company Secretary Hardik Makwana resigns effective 16 November 2026.
Subros Q2 FY27 Results: Net Profit ₹44.6 Cr, Up 9.6% YoY
Subros Ltd reported revenue from operations of ₹1,199 Cr (+36.3% YoY) and net profit of ₹44.6 Cr (+9.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹44.6 Cr · +9.6% YoY
Sumeet Industries Q2 FY27 Results: Net Profit ₹5.7 Cr, Down 42.4% YoY
Sumeet Industries Ltd reported revenue from operations of ₹364.2 Cr (+35.2% YoY) and net profit of ₹5.7 Cr (-42.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹5.7 Cr · -42.4% YoY
Yunik Managing Advisors Q2 FY27 Results: Net Profit ₹0 Cr
Yunik Managing Advisors approved unaudited standalone results for the half year ended September 30, 2026. The company reports minimal revenue and continued losses.
- Key figure
- Net profit ₹0 Cr
Pokarna Q2 FY27 Results: Net Profit ₹34.3 Cr, Up 444.4% YoY
Pokarna Ltd reported revenue from operations of ₹161.1 Cr (+35.9% YoY) and net profit of ₹34.3 Cr (+444.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹34.3 Cr · +444.4% YoY